Physician perceptions of sexual dysfunction related to benign prostatic hyperplasia (bph) symptoms and sexual side effects related to bph medications

ABSTRACT In a large-scale epidemiology study, 50% of aging men reported erectile dysfunction (ED) or ejaculatory dysfunction (EjD), with lower urinary tract symptoms (LUTS) an independent

risk factor for each of these conditions. In light of the shift from urologists (UROs) to primary care/internal medicine physicians (PCPs) for the initial management of men with LUTS

associated with benign prostatic hyperplasia (BPH), a survey was conducted to assess the perceptions of UROs and PCPs regarding sexual dysfunction (SD) in men with LUTS/BPH and the effects

of BPH treatments (_α_1-adrenergic receptor antagonists (_α_-blockers) and 5_α_-reductase inhibitors (5ARIs)) on sexual function. The survey was mailed to 7500 UROs and 2500 PCPs, with 1275

(13%) surveys returned (1087 by UROs, 177 by PCPs and 11 by other specialty). _α_-Blocker monotherapy was the most common medication prescribed by both UROs (56%) and PCPs (47%). UROs

estimated that 19% of their patients with LUTS/BPH experienced SD owing to their symptoms compared with the estimate of 27% by PCPs. UROs estimated that 19% of their patients experienced SD

owing to their BPH medication compared with the PCP estimate of 24%. The incidence of EjD owing to BPH medications estimated by UROs (32%) was higher than that estimated by PCPs (22%); the

rate of ED estimated by PCPs (34%) was higher than that estimated by UROs (23%). UROs were more aware than PCPs of the specific sexual side effects caused by _α_-blockers versus 5ARIs. These

results suggest that physicians are underestimating the prevalence of SD in men with LUTS/BPH. As men with LUTS/BPH are at increased risk for SD, physicians should be especially cognizant

of BPH treatment-related sexual side effects. Access through your institution Buy or subscribe This is a preview of subscription content, access via your institution ACCESS OPTIONS Access

through your institution Subscribe to this journal Receive 12 print issues and online access $259.00 per year only $21.58 per issue Learn more Buy this article * Purchase on SpringerLink *

Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional

subscriptions * Read our FAQs * Contact customer support SIMILAR CONTENT BEING VIEWED BY OTHERS PREMATURE EJACULATION AMONG MEN WITH ERECTILE DYSFUNCTION—FINDINGS FROM A REAL-LIFE

CROSS-SECTIONAL STUDY Article 01 August 2022 TRENDS IN REPORTED MALE SEXUAL DYSFUNCTION OVER THE PAST DECADE: AN EVOLVING LANDSCAPE Article 01 July 2020 ATTITUDES AND PREFERENCES TOWARDS

ERECTILE DYSFUNCTION TREATMENT AMONG MEN WITH FERTILITY NEEDS: INSIGHTS FROM A CLINICAL STUDY Article Open access 27 September 2024 REFERENCES * Berry SJ, Coffey DS, Walsh PC, Ewing LL . The

development of human benign prostatic hyperplasia with age. _J Urol_ 1984; 132: 474–479. Article  CAS  Google Scholar  * Calais Da Silva F, Marquis P, Deschaseaux P, Gineste JL, Cauquil J,

Patrick DL . Relative importance of sexuality and quality of life in patients with prostatic symptoms. Results of an international study. _Eur Urol_ 1997; 31: 272–280. Article  CAS  Google

Scholar  * Girman CJ, Jacobsen SJ, Tsukamoto T _et al_. Health-related quality of life associated with lower urinary tract symptoms in four countries. _Urology_ 1998; 51: 428–436. Article 

CAS  Google Scholar  * Welch G, Weinger K, Barry MJ . Quality-of-life impact of lower urinary tract symptom severity: results from the Health Professionals Follow-up Study. _Urology_ 2002;

59: 245–250. Article  Google Scholar  * Blanker MH, Bosch JL, Groeneveld FP _et al_. Erectile and ejaculatory dysfunction in a community-based sample of men 50 to 78 years old: prevalence,

concern, and relation to sexual activity. _Urology_ 2001; 57: 763–768. Article  CAS  Google Scholar  * Blanker MH, Bohnen AM, Groeneveld FP _et al_. Correlates for erectile and ejaculatory

dysfunction in older Dutch men: a community-based study. _J Am Geriatr Soc_ 2001; 49: 436–442. Article  CAS  Google Scholar  * Rosen R, Altwein J, Boyle P _et al_. Lower urinary tract

symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). _Eur Urol_ 2003; 44: 637–649. Article  Google Scholar  * Frankel SJ, Donovan JL, Peters TI _et al_.

Sexual dysfunction in men with lower urinary tract symptoms. _J Clin Epidemiol_ 1998; 51: 677–685. Article  CAS  Google Scholar  * Tubaro A, Polito M, Giambroni L, Famulari C, Gange E,

Ostardo E . Sexual function in patients with LUTS suggestive of BPH. _Eur Urol_ 2001; 40 (Suppl 1): 19–22. Article  Google Scholar  * Vallancien G, Emberton M, Harving N, van Moorselaar RJ .

Sexual dysfunction in 1,274 European men suffering from lower urinary tract symptoms. _J Urol_ 2003; 169: 2257–2261. Article  Google Scholar  * Enzlin P, Mak R, Kittel F, Demyttenaere K .

Sexual functioning in a population-based study of men aged 40-69 years: the good news. _Int J Impot Res_ 2004; 16: 512–520. Article  CAS  Google Scholar  * McCabe MP . Intimacy and quality

of life among sexually dysfunctional men and women. _J Sex Marital Ther_ 1997; 23: 276–290. Article  CAS  Google Scholar  * Braun M, Wassmer G, Klotz T, Reifenrath B, Mathers M, Engelmann U

. Epidemiology of erectile dysfunction: results of the ‘Cologne Male Survey’. _Int J Impot Res_ 2000; 12: 305–311. Article  CAS  Google Scholar  * Rosen RC, Seidman SN, Menza MA _et al_.

Quality of life, mood, and sexual function: a path analytic model of treatment effects in men with erectile dysfunction and depressive symptoms. _Int J Impot Res_ 2004; 16: 334–340. Article

  CAS  Google Scholar  * Dahn JR, Penedo FJ, Gonzalez JS _et al_. Sexual functioning and quality of life after prostate cancer treatment: considering sexual desire. _Urology_ 2004; 63:

273–277. Article  Google Scholar  * Bruskewitz R . Management of symptomatic BPH in the US: who is treated and how? _Eur Urol_ 1999; 36 (Suppl 3): 7–13. Article  Google Scholar  * Lukacs B .

Management of symptomatic BPH in France: who is treated and how? _Eur Urol_ 1999; 36 (Suppl 3): 14–20. Article  Google Scholar  * AUA guideline on management of benign prostatic

hyperplasia. Chapter 1: diagnosis and treatment recommendations. AUA Practice Guidelines Committee. _J Urol_ 2003; 170: 530–547. * Carbone Jr DJ, Hodges S . Medical therapy for benign

prostatic hyperplasia: sexual dysfunction and impact on quality of life. _Int J Impot Res_ 2003; 15: 299–306. Article  Google Scholar  * FLOMAX (tamsulosin hydrochloride) [prescribing

information] Boehringer Ingelheim Pharmaceuticals, Inc.: Ridgefield, CT, 2005. * Nickel JC, Fradet Y, Boake RC _et al_. Efficacy and safety of finasteride therapy for benign prostatic

hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study. _CMAJ_ 1996; 155: 1251–1259. CAS  PubMed  PubMed

Central  Google Scholar  * Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G . Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with

benign prostatic hyperplasia. _Urology_ 2002; 60: 434–441. Article  Google Scholar  * Baldwin K, Ginsberg P, Harkaway RC . Under-reporting of erectile dysfunction among men with unrelated

urologic conditions. _Int J Impot Res_ 2003; 15: 87–89. Article  CAS  Google Scholar  * Kitai E, Vinker S, Kijner F, Lustman A . Erectile dysfunction – the effect of sending a questionnaire

to patients on consultations with their family doctor. _Fam Pract_ 2002; 19: 247–250. Article  Google Scholar  * Hakim J, Subit M, Kandzari S, Zaslau S . Quality control in the screening of

erectile dysfunction results of a survey. _Urology_ 2002; 60: 125–129. Article  CAS  Google Scholar  * Rutchik SD, Baudiere M, Wade M, Sullivan G, Rayford W, Goodman J . Practice patterns in

the diagnosis and treatment of erectile dysfunction among family practice physicians. _Urology_ 2001; 57: 146–150. Article  CAS  Google Scholar  * Brookes ST, Donovan JL, Peters TJ, Abrams

P, Neal DE . Sexual dysfunction in men after treatment for lower urinary tract symptoms: evidence from randomised controlled trial. _BMJ_ 2002; 324: 1059–1061. Article  Google Scholar  *

Fisher W, Rosen R, Eardley I _et al_. The multinational Men's Attitides to Life Events and Sexuality (MALES) Study Phase II: understanding PDE5 inhibitor treatment seeking patterns

among men with erectile dysfunction. _J Sex Med_ 2004; 1: 150–160. Article  Google Scholar  * Wei J, Nuckolls J, Miner M, Rosen R, Roehrborn C . Differences in medical management of LUTS/BPH

between PCPs and urologists [abstract]. _J Urol_ 2006; 175: 3. Article  Google Scholar  * Kirby RS, Roehrborn C, Boyle P _et al_. Efficacy and tolerability of doxazosin and finasteride,

alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. _Urology_ 2003; 61: 119–126.

Article  Google Scholar  * Lepor H, Williford WO, Barry MJ _et al_. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies

Benign Prostatic Hyperplasia Study Group. _N Engl J Med_ 1996; 335: 533–539. Article  CAS  Google Scholar  * McConnell JD, Roehrborn CG, Bautista OM _et al_. The long-term effect of

doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. _N Engl J Med_ 2003; 349: 2387–2398. Article  CAS  Google Scholar  * Resnick M,

Seftel A, Rosen R, Roehrborn C . _Alfuzosin 10 mg improves sexual function in BPH patients: preliminary results of a placebo controlled trial. Societe Internationale d'Urologie (SIU)_.

Honolulu, Hawaii, 2004. Google Scholar  * van Moorselaar RJ, Hartung R, Emberton M _et al_. Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and

concomitant sexual dysfunction. _BJU Int_ 2005; 95: 603–608. Article  Google Scholar  * Elhilali M, Emberton M, Matzkin H _et al_. Long-term efficacy and safety of alfuzosin 10 mg once

daily: a 2-year experience in ‘real-life’ practice. _BJU Int_ 2006; 97: 513–519. Article  CAS  Google Scholar  * Kirby RS, Andersen M, Gratzke P, Dahlstrand C, Hoye K . A combined analysis

of double-blind trials of the efficacy and tolerability of doxazosin-gastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasia. _BJU

Int_ 2001; 87: 192–200. Article  CAS  Google Scholar  * De Rose AF, Carmignani G, Corbu C _et al_. Observational multicentric trial performed with doxazosin: evaluation of sexual effects on

patients with diagnosed benign prostatic hyperplasia. _Urol Int_ 2002; 68: 95–98. Article  CAS  Google Scholar  * Sairam K, Kulinskaya E, McNicholas TA, Boustead GB, Hanbury DC . Sildenafil

influences lower urinary tract symptoms. _BJU Int_ 2002; 90: 836–839. Article  CAS  Google Scholar  * Seftel AD, Sun P, Swindle R . The prevalence of hypertension, hyperlipidemia, diabetes

mellitus and depression in men with erectile dysfunction. _J Urol_ 2004; 171: 2341–2345. Article  Google Scholar  Download references ACKNOWLEDGEMENTS This survey was sponsored by The

American Foundation for Urologic Disease (AFUD) and funded through an unrestricted educational grant from sanofi-aventis. Patricia B Leinen, PhD, (Tri-Med Communications, Media, PA, USA)

contributed to the preparation of the manuscript. AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Department of Urology, Case Western Reserve University, University Hospital of Cleveland,

Cleveland, OH, USA A Seftel, R Rosen & L Kuritzky Authors * A Seftel View author publications You can also search for this author inPubMed Google Scholar * R Rosen View author

publications You can also search for this author inPubMed Google Scholar * L Kuritzky View author publications You can also search for this author inPubMed Google Scholar CORRESPONDING

AUTHOR Correspondence to A Seftel. APPENDIX A APPENDIX A RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Seftel, A., Rosen, R. & Kuritzky, L.

Physician perceptions of sexual dysfunction related to benign prostatic hyperplasia (BPH) symptoms and sexual side effects related to BPH medications. _Int J Impot Res_ 19, 386–392 (2007).

https://doi.org/10.1038/sj.ijir.3901540 Download citation * Received: 05 October 2006 * Revised: 06 December 2006 * Accepted: 27 December 2006 * Published: 22 March 2007 * Issue Date: 01

August 2007 * DOI: https://doi.org/10.1038/sj.ijir.3901540 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a

shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative KEYWORDS * benign prostatic hyperplasia *

lower urinary tract symptoms * ejaculatory dysfunction * impotence * prevalence * sexual dysfunction * drug therapy * physician survey * physician specialty